The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer

Oncology Reports

Volumn 22, Issue 3, 2009, Pages 575-579

  Lång, Anna ^a   Wegman, Pia Palmebäck ^b   Wingren, Sten ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

Author keywords

Age of onset; Breast cancer; Codon 72; Early onset; MDM2; P53; Polymorphism; SNP309

Indexed keywords

ARGININE; GUANINE; PROLINE; PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CODON; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREND STUDY; BREAST TUMOR; GENETICS; MUTATION; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; CODON; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; HUMANS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 70349316753     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000474     Document Type: Article

References (36)

1. Collaborative Group on Hormonal Factors in Breast Cancer: Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58.209 women with breast cancer and 101.986 women without the disease. Lancet 358: 1389-1399, 2001.
2. Miki Y, Swense J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994.
3. Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792, 1995.
4. Slee EA, O'Connor DJ and Lu X: To die or not to die: how does p53 decide? Oncogene 23: 2809-2818, 2004.
5. Vousden KH and Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604, 2002.
6. Sionov RV and Haupt Y: The cellular response to p53: the decision between life and death. Oncogene 18: 6145-6157, 1999.
7. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J and Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7: 961-963, 1987.
8. Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003.
9. Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199, 2004.
10. Sullivan A, Sved N, Gasco M, et al: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23: 3328-3337, 2004.
11. Papadakis EN, Dokianakis DN and Spandidos DA: P53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3: 389-392, 2000.
12. Bonafé M, Ceccarelli C, Farabegoli F, et al: Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 9: 4860-4864, 2003.
13. Tommiska J, Eeorola H, Heinonen M, et al: Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11: 5098-5103, 2005.
14. Noma C, Miyoshi Y, Taqushi T, Tamaki Y and Noquchi S: Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 210: 197-203, 2004.
15. Mabrouk I, Baccouche S, El-Abed R, et al: No evidence of correlation between p53 codon 72 polymorphism and bladder or breast carcinoma in Tunisian patients. Ann NY Acad Sci 1010: 764-770, 2003.
16. 1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16: 2445-2452, 1996.
17. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
18. Wu X, Bayle JH, Olson D and Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132, 1993.
19. Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature 387: 299-303, 1997.
20. Haupt Y, Maya R, Kazaz A and Oren M: MDM2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997.
21. Fang S, Jensen JP, Ludwig RL, Vousden KH and Weissman AM: MDM2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275: 8945-8951, 2000.
22. Honda R, Tanaka H and Yasada H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27, 1997.
23. Barak Y, Juven T, Haffner R and Oren M: MDM2 expression is induced by wild-type p53 activity. EMBO J 12: 461-468, 1993.
24. Bond GL, Hu W, Bond EE, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602, 2004.
25. Bougeard G, Baert-Desurmont S, Tournier I, et al: Impact of the MDM2 SNP309 and TP53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43: 531-533, 2006.
26. Ahmadian A, Ehn M and Hober S: Pyrosequencing: history, biochemistry and future. Clin Chim Acta 363: 83-94, 2006.
27. Gentile M, Bergman Jungestrom M, Olsen KE, Söderkvist P and Wingren S: p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur J Cancer 35: 1202-1207, 1999.
28. Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ and De Vivo I: The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses health studies. Cancer Causes Control 18: 621-625, 2007.
29. Schmidt M, Reincke S, Broeks A, et al: Do MDM2 and TP53 R73P interact in breast cancer susceptibility? A large pooled series from breast cancer association consortium. Cancer Res 67: 9584-9590, 2007.
30. Lum S, Chua H, Li H, Rao N, Wei J, Shao Z and Sabapathy K: MDM2 SNP309 allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancer in the Chinese population. Carcinogenesis 29: 754-761, 2008.
31. Wilkening S, Bermejo JL, Burwinkel B, et al: The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res 66: 646-648, 2006.
32. Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman-Menachem T, Eisenberg-Barzilia S and Friedman E: The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92: 1144-1148, 2005.
33. Ruijs MW, Schidt MK, Nevanlinna H, et al: The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Human Genet 15: 110-114, 2007.
34. Nakashima M, Kondo S, Shimizu Y, Wakisaka N, Murono S, Furukawa M and Yoshizaki T: Impact of MDM2 single nucleotide polymorphism on tumour onset in head and neck squamous cell carcinomas. Acta Otolaryngol 128: 808-813, 2008.
35. Wilkening S, Bermejo J and Hemminki K: MDM2 SNP 309 and cancer risk: a combined analysis. Carcinogenesis 28: 2262-2267, 2007.
36. Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E and Papa MZ: MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 111: 497-504, 2008